e-Edition
Obituaries
Special Sections
Special Occasions
Contact

Subscribe
Paywall Login
Login to Comment
Register

December 11th, 2017

jobs

homes

Home
News
Sports
Business
Entertainment
Classifieds
Commentary

Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

165.61 -8.78 (-5.03%)

Streaming Delayed Price Updated: 12:51 PM EST, Jan 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Sage Therapeutics Collapses 21% After Biogen-Tied Essential Tremor Drug Fails ↗

July 24, 2024

The companies are no longer developing their drug for essential tremor treatment.

Via Investor's Business Daily

If You Can Only Buy One Biotech Stock in July, It Better Be One of These 3 Names ↗

July 19, 2024

Evaluating and making money from biotech stocks is incredibly difficult. These three ideas should help your quest if buying in July.

Via InvestorPlace

How Is The Market Feeling About Jazz Pharmaceuticals? ↗

July 15, 2024

Via Benzinga

Is Big Pharma Poised To Take Over Cannabis? 3 Companies Already Manage 8 In 10 Drug Prescriptions In The US ↗

July 11, 2024

The U.S. Federal Trade Commission (FTC) recently highlighted the significant influence of pharmacy benefit managers (PBMs) on drug prices due to market consolidation. This trend raises critical...

Via Benzinga

Topics Cannabis

Avicanna Exports Cannabinoids To Singapore Legally — Even Though Cannabis Is Punishable By Death In The Country ↗

July 11, 2024

Cannabinoid-focused biopharmaceutical company Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) announced on Thursday that through its majority-owned subsidiary Santa Marta Golden Hemp the company...

Via Benzinga

Topics Cannabis

Assessing Jazz Pharmaceuticals: Insights From 7 Financial Analysts ↗

July 02, 2024

Via Benzinga

Decoding 12 Analyst Evaluations For Jazz Pharmaceuticals ↗

June 05, 2024

Via Benzinga

3 Mid-Cap Growth Rockets Trading at Deep Discounts to Their Potential ↗

July 04, 2024

Large cap stocks are where the alpha is now, but there’s a case to be made for these undervalued mid-cap growth stocks

Via InvestorPlace

7 Biotech Stocks to Boost Your Portfolio to Peak Health ↗

June 26, 2024

With biotech stocks commanding a permanently relevant narrative, you can’t afford to ignore these highly endorsed ideas.

Via InvestorPlace

3 Cannabis Stocks That Could Make Your Grandchildren Rich ↗

June 25, 2024

These cannabis stocks offer long-term growth potential anchored by solid operational models and diversified revenue streams today.

Via InvestorPlace

Topics Cannabis

Why Is Jazz Pharmaceuticals Stock Trading Lower On Thursday? ↗

June 20, 2024

Jazz Pharmaceuticals announced Phase 2b trial results for suvecaltamide (JZP385) in essential tremor patients, revealing no significant improvements over placebo.

Via Benzinga

Jazz Dives — And Takes Praxis With It — On Essential Tremor Drug Failure ↗

June 20, 2024

The companies are working on treatments for essential tremor, a tricky indication.

Via Investor's Business Daily

Demystifying Jazz Pharmaceuticals: Insights From 15 Analyst Reviews ↗

May 02, 2024

Via Benzinga

Breaking Down Jazz Pharmaceuticals: 15 Analysts Share Their Views ↗

April 10, 2024

Via Benzinga

The Analyst Landscape: 12 Takes On Jazz Pharmaceuticals ↗

March 20, 2024

Via Benzinga

3 Blue-Chip Stocks to Triple Your Wealth by 2026: June Edition ↗

June 14, 2024

These blue-chip stocks offer stability, sustainable growth and operational models less prone to wider economic fluctuations.

Via InvestorPlace

This Old Dominion Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday ↗

June 05, 2024

Via Benzinga

7 Overlooked Stocks Offering Long-Term Stability From the Shadows ↗

June 03, 2024

These overlooked stocks offer price appreciation, income, and more while diversifying across sectors and company sizes.

Via InvestorPlace

3 Cannabis Stocks to Buy Now: May 2024 ↗

May 26, 2024

These cannabis stocks to buy offer the best odds at capturing long-term upside from current rescheduling initiatives.

Via InvestorPlace

Topics Cannabis

7 Blue-Chip Stocks to Buy Now: May 2024 ↗

May 23, 2024

These blue-chip stocks to buy offer long-term price appreciation opportunities reinforced with undeniable stock stability.

Via InvestorPlace

Cannabis Meets Prescription Drugs, Steroids And Ketamine In Schedule III: What It Means, Key Stocks To Watch ↗

May 18, 2024

President Joe Biden's administration is moving to reschedule cannabis from Schedule I to Schedule III under the Controlled Substances Act (CSA).

Via Benzinga

Topics Cannabis

3 Cheap Blue-Chip Stocks to Buy Now: May 2024 ↗

May 17, 2024

If stock market speculation isn't quite working in your favor, these cheap blue-chip stocks may be the boost your portfolio needs.

Via InvestorPlace

10 Health Care Stocks With Whale Alerts In Today's Session ↗

May 15, 2024

Via Benzinga

Will Pharma And Healthcare Have Competitive Edge In Cannabis Post-Rescheduling? Data Analytics Expert Weighs In ↗

May 14, 2024

Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028.

Via Benzinga

Topics Cannabis

7 Cannabis Stocks to Buy for a Smoking-Hot 2024 ↗

May 09, 2024

Ignite your portfolio with these seven sizzling cannabis stocks. From industry leaders to innovative upstarts.

Via InvestorPlace

Topics Cannabis

The 7 Top-Selling Cannabis Companies Ranked by Revenue: Which Weed Stocks to Buy? ↗

May 08, 2024

These top cannabis stocks by revenue are among the world's best sellers, making them prime investment opportunities to capture legal changes.

Via InvestorPlace

Topics Cannabis

JAZZ Stock Earnings: Jazz Pharmaceuticals Misses EPS, Misses Revenue for Q1 2024 ↗

May 01, 2024

JAZZ stock results show that Jazz Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

3 No-Brainer Stocks to Buy With $300 Right Now ↗

April 24, 2024

A modest amount of money can go a long way on Wall Street when it's put to work in time-tested businesses with well-defined catalysts.

Via The Motley Fool

How To Make Your Cannabis Business More Attractive For Investors In 2024: Advice On Financial Health & Innovation ↗

March 25, 2024

Via Benzinga

Topics Cannabis

HC Wainwright & Co. Maintains Buy Rating for Jazz Pharmaceuticals: Here's What You Need To Know ↗

March 14, 2024

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9

...

16 17 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

More ways to get to us

Facebook

Twitter

YouTube

ePaper Login
Subscribe
Subscription Services
Archive

About Us

The Lethbridge Herald
Other Publications
Food For Thought

Contact
Careers

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

Advertising
Terms and Conditions & Privacy Policy